186 related articles for article (PubMed ID: 24711267)
41. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
[TBL] [Abstract][Full Text] [Related]
42. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Clavier JB; Antoni D; Atlani D; Ben Abdelghani M; Schumacher C; Dufour P; Kurtz JE; Noel G
Dis Esophagus; 2014 Aug; 27(6):560-7. PubMed ID: 23106980
[TBL] [Abstract][Full Text] [Related]
43. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
44. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
Horgan AM; Darling G; Wong R; Guindi M; Liu G; Jonker DJ; Lister J; Xu W; MacKay HM; Dinniwell R; Kim J; Pierre A; Shargall Y; Asmis TR; Agboola O; Seely AJ; Ringash J; Wells J; Marginean EC; Haider M; Knox JJ
Dis Esophagus; 2016 Nov; 29(8):1152-1158. PubMed ID: 26663741
[TBL] [Abstract][Full Text] [Related]
46. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
Hamai Y; Hihara J; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
Ann Thorac Surg; 2015 Jun; 99(6):1887-93. PubMed ID: 25912745
[TBL] [Abstract][Full Text] [Related]
47. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
48. Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer.
Kawaguchi Y; Nishiyama K; Miyagi K; Suzuki O; Ito Y; Nakamura S
Jpn J Clin Oncol; 2011 Aug; 41(8):1007-12. PubMed ID: 21665908
[TBL] [Abstract][Full Text] [Related]
49. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
50. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.
McNamara MJ; Adelstein DJ; Allende DS; Bodmann JW; Ives DI; Murthy SC; Raymond D; Raja S; Rodriguez CP; Sohal D; Stephans KL; Videtic GMM; Rybicki LA
J Gastrointest Cancer; 2017 Jun; 48(2):181-189. PubMed ID: 27734205
[TBL] [Abstract][Full Text] [Related]
51. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
52. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
[TBL] [Abstract][Full Text] [Related]
53. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
[TBL] [Abstract][Full Text] [Related]
54. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer.
Amini A; Ajani J; Komaki R; Allen PK; Minsky BD; Blum M; Xiao L; Suzuki A; Hofstetter W; Swisher S; Gomez D; Liao Z; Lee JH; Bhutani MS; Welsh JW
Ann Surg Oncol; 2014 Jan; 21(1):306-14. PubMed ID: 24197760
[TBL] [Abstract][Full Text] [Related]
55. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
[TBL] [Abstract][Full Text] [Related]
56. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer.
Shaikh T; Zaki MA; Dominello MM; Handorf E; Konski AA; Cohen SJ; Shields A; Philip P; Meyer JE
Acta Oncol; 2016; 55(3):303-8. PubMed ID: 26581671
[TBL] [Abstract][Full Text] [Related]
57. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?
Chan A; Wong A
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):265-70. PubMed ID: 10487544
[TBL] [Abstract][Full Text] [Related]
58. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
59. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Kersting S; Konopke R; Dittert D; Distler M; Rückert F; Gastmeier J; Baretton GB; Saeger HD
J Gastroenterol Hepatol; 2009 May; 24(5):886-95. PubMed ID: 19655439
[TBL] [Abstract][Full Text] [Related]
60. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
